ArticleFuture science OA2025
Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe analyzed immunoexpression of Dysadherin, E-cadherin and ß-catenin proteins in prostate.
methods53 radical prostatectomy specimens were included. Dysadherin, E-cadherin and ß-catenin were evaluated in prostatic adenocarcinoma and in adjacent non-tumorous tissue, and correlated with clinicomorphological features in prostatic adenocarcinoma.
resultsWe report cytoplasmic/membraneous and nuclear staining for Dysadherin in prostatic tissue. Cytoplasmic/membraneous expression was stronger in prostatic adenocarcinoma when compared to adjacent non-tumorous prostatic tissue (p < 0.001). Dysadherin positively correlated with T status (rho = 0.326, P = 0.017) and Grade Group (rho = 0.278, P = 0.044). We report no correlation with recurrence, surgical margins status, sPSA and N status. E-cadherin was negatively correlated with recurrence (rho = -0.297, P = 0.031), T status (rho = -0.430, P = 0.001), Grade Group (rho = -0.558, P < 0.001) and positive surgical margins (rho = -0.404, P = 0.003). ß-catenin negatively correlated with Grade Group (rho = -0.557, P < 0,001). No correlation was observed between Dysadherin and E-cadherin and Dysadherin and ß-catenin expression.
conclusionOur results suggest a potential role for Dysadherin in tumor progression. No significant correlation between Dysadherin and E-cadherin or ß-catenin indicates potential independence of Dysadherin in its regulatory role in prostatic adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.